Bildkälla: Stockfoto

BONESUPPORT Q3: Initial take – sales in line, beat on EBIT - Redeye

Redeye sees another quarter in which BONESUPPORT delivers well on sales (beating our US CERAMENT G sales figures), and we expect the market to appreciate the robust EBIT. In short, Q3 was a solid quarter, but the report should not send any shockwaves today. We expect a 2-3% positive share price reaction.

Redeye sees another quarter in which BONESUPPORT delivers well on sales (beating our US CERAMENT G sales figures), and we expect the market to appreciate the robust EBIT. In short, Q3 was a solid quarter, but the report should not send any shockwaves today. We expect a 2-3% positive share price reaction.
Börsvärldens nyhetsbrev
ANNONSER